3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
56
Lung Neoplasms
29
Triple Negative Breast Neoplasms
13
Breast Neoplasms
13
Ovarian Neoplasms
12
Endometrial Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Small Cell Lung Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Neoplasms
10
Fallopian Tube Neoplasms
10
Neoplasm Metastasis
8
Colorectal Neoplasms
5
Adenocarcinoma of Lung
5
Carcinoma
4
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Melanoma
3
Lung Diseases
3
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thoracic Neoplasms
2
Sarcoma
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Non-squamous Non-small Cell Lung Cancer
2
Interventions
Carboplatin
2
repotrectinib
1
pembrolizumab
1
durvalumab
1
Pemetrexed
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Bronchial Neoplasms
×
Carboplatin
×
30 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled
NCT07279935
2026-06-01
REVIVE
AstraZeneca
Phase 4
Recruiting
100 enrolled